Regulation_NN
of_IN
glucocorticoid_NN
receptors_NNS
in_IN
human_JJ
mononuclear_JJ
cells_NNS
:_:
effects_NNS
of_IN
glucocorticoid_NN
treatment_NN
,_,
Cushing_NN
's_POS
disease_NN
and_CC
ketoconazole_NN
._.

Glucocorticoid_NN
receptors_NNS
-LRB-_-LRB-
GcR_NN
-RRB-_-RRB-
were_VBD
determined_VBN
by_IN
a_DT
whole_JJ
cell_NN
assay_NN
in_IN
human_JJ
mononulear_JJ
leukocytes_NNS
-LRB-_-LRB-
hMNL_NN
-RRB-_-RRB-
from_IN
control_NN
subjects_NNS
,_,
patients_NNS
receiving_VBG
glucocorticoid_NN
therapy_NN
for_IN
systemic_JJ
diseases_NNS
and_CC
Cushing_NN
's_POS
disease_NN
patients_NNS
with_IN
or_CC
without_IN
ketoconazole_NN
therapy_NN
._.

Prolonged_JJ
corticosteroid_NN
treatment_NN
resulted_VBD
in_IN
down-regulation_NN
of_IN
GcR_NN
,_,
while_IN
the_DT
mean_JJ
level_NN
of_IN
GcR_NN
in_IN
Cushing_NN
's_POS
disease_NN
was_VBD
normal_JJ
._.

In_IN
this_DT
group_NN
,_,
however_RB
,_,
receptor_NN
levels_NNS
and_CC
morning_NN
plasma_NN
cortisol_NN
values_NNS
showed_VBD
a_DT
negative_JJ
correlation_NN
,_,
indicating_VBG
a_DT
subtle_JJ
down-regulatory_JJ
effect_NN
._.

Furthermore_RB
,_,
GcR_NN
were_VBD
unaltered_JJ
after_IN
these_DT
patients_NNS
received_VBD
ketoconazole_NN
,_,
in_IN
spite_NN
of_IN
a_DT
marked_JJ
reduction_NN
in_IN
morning_NN
plasma_NN
cortisol_NN
and_CC
urinary_JJ
free_JJ
cortisol_NN
._.

We_PRP
also_RB
observed_VBD
that_IN
ketoconazole_NN
was_VBD
a_DT
weak_JJ
competitor_NN
of_IN
GcR_NN
in_IN
intact_JJ
cells_NNS
,_,
although_IN
it_PRP
significantly_RB
inhibited_VBD
-LCB-_-LRB-
3H-RCB_CD
-_:
dexamethasone_NN
binding_NN
in_IN
cytosolic_JJ
preparations_NNS
from_IN
rat_NN
tissues_NNS
._.

The_DT
results_NNS
suggested_VBD
that_IN
GcR_NN
in_IN
hMNL_NN
are_VBP
down-regulated_VBN
by_IN
synthetic_JJ
steroids_NNS
given_VBN
in_FW
vivo_FW
,_,
but_CC
they_PRP
showed_VBD
very_RB
mild_JJ
down-regulation_NN
in_IN
hypercortisolemic_JJ
patients_NNS
suffering_VBG
from_IN
Cushing_NN
's_POS
disease_NN
._.

Finally_RB
,_,
we_PRP
did_VBD
not_RB
observed_VBN
either_CC
up-regulation_NN
or_CC
antagonism_NN
of_IN
GcR_NN
by_IN
ketoconazole_NN
treatment_NN
,_,
at_IN
the_DT
time_NN
that_IN
cortisol_NN
levels_NNS
of_IN
patients_NNS
with_IN
Cushing_NN
's_POS
disease_NN
were_VBD
reduced_VBN
._.

This_DT
indicates_VBZ
that_IN
the_DT
beneficial_JJ
effects_NNS
of_IN
ketoconazole_NN
in_IN
Cushing_NN
's_POS
disease_NN
are_VBP
due_JJ
to_TO
adrenal_JJ
cortisol_NN
suppression_NN
and_CC
not_RB
to_TO
interaction_NN
with_IN
GcR_NN
of_IN
target_NN
cells_NNS
,_,
and_CC
that_IN
the_DT
process_NN
of_IN
GcR_NN
regulation_NN
in_IN
hMNL_NN
is_VBZ
a_DT
complex_JJ
phenomenon_NN
awaiting_VBG
further_JJ
elucidation_NN
._.

